Huntington's Disease News and Research

Latest Huntington's Disease News and Research

New way to protect neurons that express mutant huntingtin proteins

By using a model, researchers at the University of Montreal have identified and "switched off" a chemical chain that causes neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis and dementia. The findings could one day be of particular therapeutic benefit to Huntington's disease patients. "We've identified a new way to protect neurons that express mutant huntingtin proteins," explained Dr. Alex Parker of the University of Montreal's Department of Pathology and Cell Biology and its affiliated CRCHUM Research Centre.

27 Nov 2012

Alnylam advances Tuschl II patent estate through the USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from the company's exclusively held Tuschl II patent estate.

26 Nov 2012

Hsp104 protein switches mechanism to break up amyloid versus disordered clumps

Several fatal brain disorders, including Parkinson's disease, are connected by the misfolding of specific proteins into disordered clumps and stable, insoluble fibrils called amyloid. Amyloid fibrils are hard to break up due to their stable, ordered structure. For example, α-synuclein forms amyloid fibrils that accumulate in Lewy Bodies in Parkinson's disease. By contrast, protein clumps that accumulate in response to environmental stress, such as heat shock, possess a less stable, disordered architecture.

20 Nov 2012

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose parkinsonian syndromes.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

University of Tübingen heads Neuromics consortium

Work has begun on Neuromics, a major project headed by Tübingen's Professor Olaf Riess; the project beat out ten other first-class applications to attain €12m euros in EU funding over five years.

8 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

2 Nov 2012

XJB-5-131 compound suppresses symptoms of Huntington's in mice

There's new hope in the fight against Huntington's disease. A group of researchers that includes scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have designed a compound that suppresses symptoms of the devastating disease in mice.

2 Nov 2012

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Omeros Corporation today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.

1 Nov 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Novel insight into impact that Huntington's disease has on the brain

A study led by researchers at Boston University School of Medicine (BUSM) provides novel insight into the impact that Huntington's disease has on the brain.

19 Oct 2012

Scientists discover how protein deficiency may be linked to frontotemporal dementia

Using animal models, scientists at the Gladstone Institutes have discovered how a protein deficiency may be linked to frontotemporal dementia (FTD)-a form of early-onset dementia that is similar to Alzheimer's disease. These results lay the foundation for therapies that one day may benefit those who suffer from this and related diseases that wreak havoc on the brain.

9 Oct 2012

Lecture to discuss insights into genes and neurodegenerative diseases gleaned from baker's yeast

Insights into our genes and neurodegenerative diseases gleaned from humble baker's yeast, among other things, will be showcased by genetics experts at a free public lecture.

4 Oct 2012

Teva concludes Asset Transfer Agreement with NeuroSearch

Teva Pharmaceutical Industries Ltd announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark to purchase all rights, assets and obligations relating to Huntexil (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease (HD).

28 Sep 2012

Blood test for monitoring Huntington’s disease may be possible in future

Measuring blood levels of mutant huntingtin protein may provide an alternative approach of determining the onset of Huntington’s disease in known carriers, researchers report.

26 Sep 2012

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira Pharmaceuticals Corporation's motion to dismiss certain claims and motion to disqualify Alnylam's counsel in an infringement suit filed in January 2012.

26 Sep 2012

Researchers identify 21 proteins that specifically bind to ataxin-1

Misfolded proteins can cause various neurodegenerative diseases such as spinocerebellar ataxias (SCAs) or Huntington's disease, which are characterized by a progressive loss of neurons in the brain. Researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, together with their colleagues of the Universit- Paris Diderot, Paris, France, have now identified 21 proteins that specifically bind to a protein called ataxin-1.

19 Sep 2012

New light-based technique demonstrates that toxic proteins build up gradually in blood cells

A new light-based technique for measuring levels of the toxic protein that causes Huntington's disease (HD) has been used to demonstrate that the protein builds up gradually in blood cells. Published today (17th) in the Journal of Clinical Investigation, the findings shed light on how the protein causes damage in the brain, and could be useful for monitoring the progression of HD, or testing new drugs aimed at suppressing production of the harmful protein.

18 Sep 2012

People with genetic mutation for Huntington's disease learn faster: Study

People who bear the genetic mutation for Huntington's disease learn faster than healthy people. The more pronounced the mutation was, the more quickly they learned. This is reported by researchers from the Ruhr-Universität Bochum and from Dortmund in the journal Current Biology.

15 Sep 2012

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

New way to protect neurons that express mutant huntingtin proteins

Alnylam advances Tuschl II patent estate through the USPTO

Hsp104 protein switches mechanism to break up amyloid versus disordered clumps

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

University of Tübingen heads Neuromics consortium

Alnylam third quarter 2012 revenues decrease to $16.8 million

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

XJB-5-131 compound suppresses symptoms of Huntington's in mice

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Novel insight into impact that Huntington's disease has on the brain

Scientists discover how protein deficiency may be linked to frontotemporal dementia

Lecture to discuss insights into genes and neurodegenerative diseases gleaned from baker's yeast

Teva concludes Asset Transfer Agreement with NeuroSearch

Blood test for monitoring Huntington’s disease may be possible in future

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Researchers identify 21 proteins that specifically bind to ataxin-1

New light-based technique demonstrates that toxic proteins build up gradually in blood cells

People with genetic mutation for Huntington's disease learn faster: Study

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in